HC Wainwright & Co. Reiterates Buy on Avadel Pharmaceuticals, Maintains $21 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Oren Livnat has reiterated a 'Buy' rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a price target of $21.

August 10, 2023 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avadel Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $21.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Avadel Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100